Formoterol Fumarate API (active pharmaceutical ingredient) is a long-acting β2-adrenergic agonist used in the management of asthma and chronic obstructive pulmonary disease (COPD).

The API is a potent bronchodilator formulated for inhalation dosage forms, including dry powder inhalers (DPIs), metered-dose inhalers (MDIs), and nebulizer solutions.

Formoterol Fumarate API works by selectively stimulating β2-adrenergic receptors in bronchial smooth muscle, leading to relaxation of the airways.

This results in a rapid onset and prolonged bronchodilation, helping to improve airflow and breathing.

Formoterol Fumarate API is a fine, crystalline powder with high potency, requiring precise dose uniformity. It exhibits good chemical stability and is suitable for low-dose inhalation formulations where consistent particle size and purity are critical.

Formoterol Fumarate API is designed to support reproducible aerosol performance and uniform drug delivery in inhalation dosage forms.

Formoterol Fumarate API is primarily used in inhalation dosage forms such as dry powder inhalers (DPIs), metered-dose inhalers (MDIs), and nebulizer solutions. It is also widely formulated in fixed-dose combination products with corticosteroids for the management of respiratory conditions such as asthma and COPD.

Additionally, the low-dose potency of Formoterol Fumarate API makes it suitable for controlled pulmonary drug delivery systems.

Gangwal Healthcare supplies Formoterol Fumarate API manufactured under stringent quality systems and aligned with major pharmacopoeial standards.

Formoterol Fumarate API complies with major pharmacopoeial standards, making it suitable for use in regulated inhalation formulations. Additionally, its batch-to-batch consistency ensure reliable performance during formulation development and commercial inhalation dosage form manufacturing.